Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Martijn J H G SimonsValesca P RetèlBram L T RamaekersRogier ButterJoanne M MankorMarthe S PaatsJoachim G J V AertsZakile A MfumbilwaPaul RoepmanVeerle M H CoupéCarin A Uyl-de GrootWillem H van HartenManuela A JoorePublished in: PharmacoEconomics (2021)
Our analysis suggests that providing WGS as a diagnostic test is cost effective compared with SoC followed by WGS and SoC alone if costs for WGS decrease and additional patients with actionable targets are identified. This cost-effectiveness model can be used to incorporate new findings iteratively and to support ongoing decision making regarding the use of WGS in this rapidly evolving field.
Keyphrases